EMMA — Emmaus Life Sciences Income Statement
0.000.00%
- $4.41m
- $32.26m
- $29.60m
- 40
- 99
- 30
- 56
Annual income statement for Emmaus Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 22.8 | 23.2 | 20.6 | 18.4 | 29.6 |
Cost of Revenue | |||||
Gross Profit | 21.7 | 20.9 | 17.3 | 15.8 | 28.3 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 28 | 24.6 | 27.1 | 25.5 | 26.9 |
Operating Profit | -5.26 | -1.46 | -6.49 | -7.09 | 2.72 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -54.7 | 0.973 | -15.9 | -10.6 | -3.79 |
Provision for Income Taxes | |||||
Net Income After Taxes | -54.8 | 1.35 | -15.9 | -10.6 | -3.73 |
Net Income Before Extraordinary Items | |||||
Net Income | -54.8 | 1.35 | -15.9 | -10.6 | -3.73 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -54.8 | 1.35 | -15.9 | -10.6 | -3.73 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -1.29 | 0.047 | -0.319 | -0.208 | -0.06 |